Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760889 · ClinicalTrials.gov registry record · Phase 3
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT01760889 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 1 participants.
The verdict
NCT01760889, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
Interventions
- DRUG Placebo
- DRUG SPD489 low dose range (40mg, 80mg, and 100mg)
- DRUG SPD489 high dose range (120mg, 140mg and 160mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2013-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01760889
The ClinicalTrials.gov registry entry for NCT01760889 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01760889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01760889 about?
NCT01760889 is a clinical study titled "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia". The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
What is the current status of trial NCT01760889?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2013-02-01. Estimated completion is 2013-04-01.
What interventions are being tested in trial NCT01760889?
The interventions under investigation include: Placebo (DRUG), SPD489 low dose range (40mg, 80mg, and 100mg) (DRUG), SPD489 high dose range (120mg, 140mg and 160mg) (DRUG).
Who is sponsoring clinical trial NCT01760889?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.